Jul. 25 at 1:19 AM
$ADAP 🚀 One of the Most Underrated Biotech Plays Out There? 🚀
------Undervalued stock
1️⃣ Despite launching a commercial product and generating real revenue, Adap’s market cap is sitting at just
$70M–90M. That’s insanely low for a company with fundamentals!
2️⃣ Lete-cel has received FDA Breakthrough Therapy Designation, and a BLA rolling submission is expected by Q4 2025. Major commercial milestones ahead!
3️⃣ Analyst consensus: Mostly BUY ratings, with price targets ranging from
$1.40 to
$1.70+.
📊 Q1 2025 (March quarter) revenue came in at
$7.3M, up 28% YoY — showing strong post-launch stability.
💡 TTM revenue is now
$179.6M, up a massive 195% YoY — growth is real and accelerating.
👩🔬 Backed by ~506 employees, strong manufacturing capabilities (27-day avg turnaround, 100% success rate), and the commercial launch of TECELRA, this isn’t just a biotech dream — it’s a company with substance.
$INAB $PSTV $LIDR $IXHL